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liposomal gelIn the absence of an effective vaccine against HIV, it is urgent to develop an effective alternative such as a
microbicide. Single and repeated applications of MC1220 microbicide were evaluated in macaques. First,
animals were given a single application of 0.5% or 1.5% MC1220-containing liposomal gel. A second group
were treated with 0.5% MC1220 once a day for 4 days. The control groups were treated by liposomal gel
alone. Thirty minutes after the last application, animals were challenged with RT-SHIV. In the ﬁrst protocol, 2
of 4 animals treated by 0.5% of the MC1220 and 2 of 5 treated by 1.5% were protected. In the second protocol,
3 of 5 treated animals were protected and 5 of 5 controls were infected. The RNA viral load at necropsy was
signiﬁcantly lower (p=0.05) in treated-infected animals than in controls. In both protocols, the number of
CD4+ T cells was lower at viremia peak in infected than in protected animals.ngui, Central African Republic.
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Human immunodeﬁciency virus type 1 (HIV-1) is the main
sexually transmitted infection worldwide, affecting approximately
34 million people (Garcia-Lerma et al., 2008). About 2.5 million
people are newly infected each year, and 2.1 million of them die,
adding to the 19 million people who have already died from diseases
associated with this infection (McGowan, 2006). In the absence of an
effective HIV-1 vaccine, the virus continues to spread, with the
highest prevalence of infection in developing countries, especially in
sub-Saharan Africa and South-East Asia (Klausner et al., 2003).
Transmission in Africa is usually heterosexual, and women now
account for nearly 50% of the prevalence of HIV/AIDS worldwide
(Ambrose et al., 2007) and, unfortunately, few people use condoms to
limit the spread of HIV. Therefore, in addition to more effectivetherapeutic tools, there is an urgent need for cost-effective preventive
measures to prevent the spread of HIV/AIDS.
Microbicides are user-friendly, convenient and readily available
and would extend the range of means for self-protection against
HIV, both in developing and industrialized countries. They limit
sexual transmission of the virus (Stone, 2002) by acting on the
epithelial barrier of the vaginal and cervical mucosa, which have
been implicated in HIV transmission (Galvin and Cohen, 2004).
Microbicides must be safe, effective, affordable and acceptable. They
should not cause local irritation or epithelial damage, and they
should inhibit the virus at its point of entry through the vaginal
mucosa, prevent all subsequent steps leading to infection of the
host, block viral replication and have a high genetic barrier to
resistance (McGowan, 2006; Veazey et al., 2005). Microbicides
would appear to be a good preventive method before intercourse
(Shattock and Moore, 2003).
Despitemore than 20 years of research, however, nomicrobicide is
currently available to provide sterilizing immunity against HIV-1
(Duerr et al., 2006). Of the different types of microbicide, only two
Table 1
Mean vaginal irritation scores for monkeys treated with the microbicide MC1220
incorporated in liposome or with the liposomal gel alone (controls).
Vaginal component
(range of possible
score)
Control
liposome
alone
MC1220
0.1% gel+liposome 0.5% gel+liposome
Erythema 1.02±0.3 0.78±0.36 0.4±0.26
Oedema 0.42±0.32 0.3±0.24 0.16±0.17
Total score 1.44 1.08 0.56
The individual irritation score was assigned on the basis of a semi-quantitative scoring
system for inﬂammation: 0=none, 1=minimal, 2=mild, 3=moderate, 4=intense.
The cumulative scores for erythema and Oedema formation were: b 4=acceptable, 5–
6=marginal andN6=unacceptable
226 M. Caron et al. / Virology 405 (2010) 225–233have been tested in phase III trials, PRO2000® and Carraguard®
(Abdool Karim, 2010; Skoler-Karpoff et al., 2008) but it is difﬁcult to
predict whether these microbicides will have a beneﬁcial or a
deleterious effect on HIV transmission (Teleshova et al., 2008). As a
proved spermicide tested to prevent against sexually transmitted
diseases, the Nonoxynol-9 reduced the susceptibility of gonorrhoea
infections otherwise increased the frequency of genital ulcers and
vulvitis (Kreiss et al., 1992; Roddy et al., 1998). In clinical trials,
microbicides beneﬁt is not deftly evaluated even though a moderate
effect was statically monitored. The microbicides efﬁcacy might
depend on adherence variability to the trial, independently to the
action mechanism of microbicides.
Microbicides that speciﬁcally inhibit HIV transmission include
monoclonal antibodies against envelope glycoproteins (gp120),
attachment receptors and chemokine co-receptors (CCR5 or CXCR4)
(Hu et al., 2004; Jiang et al., 2005; Schols, 2004; Veazey et al., 2003);
inhibitors of fusion between HIV and its target cells (Derdeyn et al.,
2000; Kilby et al., 1998); and reverse transcriptase (RT) inhibitors
(Van Herrewege et al., 2004a,b). In the last substance category, several
have been already tested in phase II clinical trials as Tenofovir®, UC-
781® or TMC-120® (McGowan, 2006); others are tested in preclinical
trials (Ambrose et al., 2007). MC1220 is a non-nucleoside RT inhibitor
(NNRTI) microbicide of the 3,4-dihydro-2-alkoxy-6-benzyl-4-oxo-
pyrimidines (DABOs) series. Pani et al. (2001) demonstrated the
ability of DABOs to suppress HIV replication for an entire experimen-
tal period of 40 days with no cytotoxicity indication. This property
correlates with their ability to tightly bind to the HIV-1 reverse
transcriptase. Furthermore, of these series, MC1220 was with the
highest in vitro potential, showing a “memory effect,” i.e. the
capability of knocking out HIV replication in freshly infected cells
after a 4-h treatment followed by incubation of the extensively
washed infected culture in the continuous absence of the drug. We
hypothesized thatMC1220 could inhibit the intravaginal transmission
of HIV by hindering the conversion of viral RNA into DNA, resulting in
a reduction to viral integration. In preclinical trials, various in vitro
models were tested and then, in vivo. Veazey et al. have demonstrated
a dose-dependent protection by monoclonal antibody against vaginal
HIV transmission in non-human primates (Veazey et al., 2003).
Therefore, rhesus macaques seem well-established in vivo models for
the HIV-1 transmission (Harouse et al., 2001).
In this study, we evaluated the protective efﬁcacy of MC1220 in a
non-human primate model: adult female rhesus macaques. Dose and
time effects of MC1220 in preventing the vaginal transmission of
SHIV89.6P were evaluated by single and repeated applications.
Animals were followed up virologically and immunologically to
determine the RNA viral load, the DNA proviral load (in peripheral
blood mononuclear cells (PBMCs)), antibody responses, immunolog-
ical changes (evolution of T-cell subsets) and the viral and proviral
load in PBMCs and various lymphoid organs at necropsy.Results
Irritation effect after intravaginal treatment
The scores for irritation, as measured by the previously described
methods (D'Cruz et al., 2003), produced after two doses of MC1220
microbicide incorporated into liposomal gel are summarized in
Table 1. Little irritation was seen, with mean scores of 1.08 with
0.1% and 0.56 with 0.5% MC1220. The most irritation was observed
in the control group treated by the liposomal gel without micro-
bicide (total score, 1.44), which was signiﬁcantly different (p=
0.002) of the result from the animals group treated by liposomal
gel containing 0.5% MC1220 (total score, 0.5). No erythema or
edema was detected with 1.5% MC1220 in liposomal gel (data not
shown).Plasma viral load and PBMC proviral load after challenge
In Protocol 1 (single application, Fig. 1), four of ﬁve control animals
became infected after challenge, with high plasma viremia (107–108
copies/ml) and a high proviral load at week 2 after challenge (Fig. 2A).
In contrast, no virus was detected in PBMCs of two of the four animals
(#R08 and #R09) treated by 0.5%MC1220 (Fig. 2B) and two of the ﬁve
animals (#R11 and #R13) treated by 1.5% MC1220 (Fig. 2C).
In Protocol 2 (repeated applications), all ﬁve control animals
became infected after challenge, with high plasma viral load (106–109
copies per ml) and high proviral load (104–106 copies per 106 PBMCs)
(Fig. 2D). RT-SHIVwas not detected, however, in the plasma or PBMCs
of three of the ﬁve animals treated four times by 0.5% MC1220 during
the 8 weeks after challenge (Fig. 2E).
Virus isolation from PBMCs of treated and challenged animals
In order to conﬁrm the above observations, we isolated the virus
from PBMCs at various times after challenge. As seen in Fig. 3, the
results conﬁrmed those obtained for the plasma viral load and the
proviral load. RT-SHIV could not be isolated from one control animal
in Protocol 1, but all the other animals were positive. In the groups
treated by 0.5% and 1.5% MC1220, RT-SHIV was isolated from two of
four and three of ﬁve animals, respectively (Fig. 3A, B, C). RT-SHIVwas
isolated from one animal (#R14) at week 3 after challenge but not
thereafter (Fig. 3C).
In Protocol 2, RT-SHIV was isolated from all the control animals
(Fig. 3D) but from only two of ﬁve animals treated four times by 0.5%
MC1220 (Fig. 3E). The virus was not found in PBMCs of the remaining
three animals (#R21, #R22, #R24) during the 14 weeks of this study
(Fig. 3E).
Evaluation of antibody responses after challenge
The antibody response to RT-SHIV was evaluated by ELISA at
various times after challenge. All RT-SHIV-infected animals in both
protocols developed antibodies to RT-SHIVSIVmac239 proteins; howev-
er, no antibodieswere detected in protected animals, i.e. animals #R08
and #R09 treated by 0.5% MC1220, #R11 and #R13 treated by 1.5%
MC1220 in Protocol 1 and animals #R21, #R22 and #R24 treated four
times by 0.5% MC1220 in Protocol 2 (online supplementary data 1).
RT-SHIV isolation and proviral load in organs after necropsy
In order to evaluate the efﬁciency of MC1220 in inducing complete
protection, all animals were necropsied 14 weeks after challenge. RT-
SHIV was isolated by co-culture from various organs of control group,
although animal #R04 appeared to be negative in Protocol 1. No RT-
SHIV was found in 50% of animals treated by 0.5% or 1.5% MC1220.
Furthermore, in the group treated by 1.5%MC1220, the cell-associated
viral load in lymph nodes was lower than in the other groups or
undetectable. In Protocol 2, RT-SHIV was detected in all organs of
Fig. 1. Treatment protocol. (A) Protocol 1, a single application of 0.5% and 1.5% MC1220 incorporated into liposomal gel (9 treated and 5 control animals). (B) Protocol 2, repeated
applications–four times at one day interval before the challenge day–of 0.5% MC1220 incorporated into liposomal gel (5 treated and 5 control animals). Animals were challenged
intravaginally, 30 min after the single or last application, with 4.105 TCID50 of RT-SHIV.
Fig. 2. RT-SHIV plasma viral and PBMC proviral load at various time after challenge. (A, B, C) Protocol 1 (single application): (A) ﬁve control animals treated by the liposomal gel
alone; (B) four animals treated by 0.5%MC1220; (C) ﬁve animals treated by 1.5%MC1220. (D, E) Protocol 2 (repeated applications): (D) ﬁve control animals treated by the liposomal
gel alone; (E) ﬁve animals treated four times by 0.5% MC1220. Plasma viral load (RNA) is in red and PBMC proviral load is in blue (DNA).
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Fig. 3. Cell-associated viral load from PBMCs over time after intravaginal challenge with RT-SHIV. (A, B, C) Protocol 1 (single application): (A) ﬁve control animals treated by the
liposomal gel alone; (B) four animals treated by 0.5%MC1220; (C) ﬁve animals treated by 1.5%MC1220. (D, E) Protocol 2 (repeated applications): (D) ﬁve control animals treated by
the liposomal gel; (E) ﬁve animals treated four times by 0.5% MC1220.
228 M. Caron et al. / Virology 405 (2010) 225–233control group but in only two of the ﬁve animals treated four times by
0.5% MC1220 (online supplementary data 2).
The presence of RT-SHIV in organswas also evaluated byRT-PCR and
real-timePCR.As shown inTable 2, all the control animalswere positive,
except animal #R04 in Protocol 1. Organs from two animals treated by
0.5% MC1220 (#R08 and #R09) and two animals treated by 1.5%
MC1220 (#R11 and #R12)were negative. In Protocol 2, the organs from
control animals were all positive, but no RT-SHIV was detected in three
animals (#R21, #R22, #R24) treated four times by 0.5% MC1220.
The mean viral load of all organs was compared for control and
treated but infected animals. As shown in Fig. 4B, the RNA viral load at
necropsy (week 14) was signiﬁcantly lower (p=0.05) in the infected
animals treated in Protocol 2 than in control group. No signiﬁcant
difference was found in Protocol 1 (Fig. 4A).Evaluation of T-cell subsets in PBMCs and organs at necropsy
T-cell subsets were evaluated before and during the 14 weeks after
challenge in controls, treated–infected and protected animals and
then, at necropsy in several lymphatic organs (online supplementary
data 3). The number of CD4+ T-cells had decreased signiﬁcantly in
control and treated–infected animals at the week 4, but not in the
protected group. The lowest number of CD4+ T-cells was found at the
week 6 in controls and treated–infected animals, while the number of
CD4+ T-cells was signiﬁcantly higher in the protected animals than in
other groups.
The evolution of CD8+ T-cells during the study was evaluated in
the same groups. No signiﬁcant difference was found in the number ofCD8+T-cells in PBMCs; however, the numberwas signiﬁcantly higher
in control animals than in treated–infected and protected animals.
At necropsy, no signiﬁcant difference between groups was found
in the percentages of various T-cell subsets in the organs. Neverthe-
less, the percentage of effector memory T-cells in CD8+ T-cells in the
axillary, inguinal and iliac lymph nodes of the protected animals
was signiﬁcantly lower than in the other infected groups (data not
shown).Discussion
In this study, we demonstrated that the MC1220 microbicide is
able to induced partial protection in treated animals compared to the
controls. Seven out of 14 animals that received the microbicide were
uninfected after challenge, compared to 1 out of the 10 controls
(pb0.05). In Protocol 1, no signiﬁcant difference was found in relation
to the dose used. However, in the group treated with 1.5%, the cell-
associated viral load in the lymph nodes was lower than in monkeys
treated with 0.5%. When repeated applications of the microbicide
were given, three of the ﬁve treated animals were protected, and the
two infected animals had a lower plasma viral load than the control
group. Our data demonstrated that treatment with MC1220 is also
able to reduce the virus load in treated infected animals.
We also showed that the number of CD4+ T-cells decreased
signiﬁcantly in both the control group and in treated but infected
animals 6 weeks after intravaginal challenge. In protected animals
treated by single or repeated applications, however, the number of
CD4+ T-cells was stable, showing that MC1220 induced protection.
Table 2
RT-SHIV plasma viral load and proviral load in PBMCs and various organs after necropsy.
Control Group 0.5% MC1220 treatment 1.5% MC1220 treatment
Variable R01 R02 R03 R04 R05 R06 R07 R08 R09 R10 R11 R12 R13 R14
(A) Monkeys treated in protocol 1, with a single application of the microbicide
Viral loada
Plasma 2.1×104 1.2×105 b102 – 9.5×104 1.6×106 2.2×106 – – 1.2×104 – 1.6×105 −b102
Proviral loadb
PBMCs 3.3×105 8.3×104 4.5×104 – 5.4×104 3.8×105 2.5×106 – – 1.9×105 – 3.0×106 – 5.8×104
Spleen 1.6×104 1.1×106 1.8×105 – 2.2×105 5.7×105 9.4×105 – – 6.1×104 – 9.8×105 – 4.9×103
Lymph nodes
Axillary 4.5×105 2.1×106 4.2×104 – 4.7×104 1.5×105 1.9×106 – – 1.2×105 – 6.9×105 – 2.3×104
Mesenteric 7.7×105 3.1×106 4.0×105 – 1.7×105 3.7×105 1.3×106 – – 7.1×105 – 1.8×106 – 3.2×104
Ilialic 1.6×106 1.2×106 3.7×104 – 1.8×105 6.1×105 2.3×106 – – 5.9×105 – 3.9×106 – 6.9×103
Inguinal 3.2×105 3.3×106 2.7×104 – 3.2×103 2.5×105 4.7×105 – – 4.3×104 – 4.9×106 – 1.6×104
Control Group 4×0.5%MC1220 treatment
Variable R15 R16 R17 R18 R19 R20 R21 R22 R23 R24
(B) Monkeys treated in protocol 2, with multiple applications of the microbicide
Viral loada
Plasma 1.6×107 1.4×107 1.1×106 3.8×106 1.9×106 3.0×105 – – 9.4×105 –
Proviral loadb
PBMCs 2.4×106 1.6×106 1.1×106 7.2×105 4.1×106 5.0×106 – – 1.6×107 –
Spleen 6.5×106 5.1×106 2.6×106 5.7×106 2.2×106 2.6×106 – – 2.0×107 –
Lymph nodes
Axillary 6.6×106 5.2×106 7.5×105 3.3×106 2.3×106 4.2×106 – – 1.9×107 –
Mesenteric 4.8×106 4.7×106 2.2×106 4.5×106 7.9×105 1.3×106 – – 2.1×107 –
Ilialic 4.1×106 3.8×106 1.6×106 4.8×106 2.3×106 2.1×106 – – 2.1×107 –
Inguinal 3.4×106 1.3×106 2.7×107 2.5×106 1.1×106 1.8×107 – – 1.9×107 –
a RNA copies/mL.
b Copies/μg of DNA.
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detection in any of the protected animals. These results conﬁrm that
MC1220 is effective in inducing complete protection after challenge.
One limitation of our study, however, is the small number of
macaques in each group, and further experimental studies are needed
to conﬁrm our observations.
Research on microbicides is evolving rapidly. It is estimated that
60–80 products are currently in development, most of which are in
preclinical evaluation and have already been evaluated in vitro. Many
candidates, involving various routes, formulations and combinations,
are being tested, although it is critical that they do not have to be used
in a coitally dependent fashion (McGowan, 2006). NNRTIs may be
suitable as they inhibit RT and thus suppress the conversion of viral
RNA into DNA before integration into the host genome, resulting inFig. 4. Plasma viral load at necropsy (14 weeks after challenge) in control and treated but i
between control and treated animals. (B) Protocol 2 (repeated applications), with a signiﬁcalarge reductions in viral replication. Two main types of microbicides
are being studied: those for oral therapy and topical agents. Several
topical products are under clinical development at a reasonable
production cost, and many studies with animal models suggest that
they are effective. A possible disadvantage, however, is that micro-
bicides that are RT inhibitorsmight result in antiretroviral resistance if
patients use the products for a long time or at a low repeated dose.
Three RT inhibitor microbicides are under clinical assessment:
Tenofovir®, UC-781® and TMC-120®. Tenofovir has been evaluated in
non-human primates, with 56% efﬁcacy after either cervical or rectal
challenge (Cranage et al., 2008). UC-781® is also a rectal and vaginal
microbicide but has reduced activity against NNRTI-resistant HIV-1
(Hossain and Parniak, 2006). TMC-120® had high activity against
wild-type and mutant HIV (D'Cruz and Uckun, 2006). Attackingnfected animals after challenge. (A) Protocol 1 (single application), with no difference
ntly lower plasma viral load (p=0.05) in treated but infected than in control animals.
Table 3
Gelling agents and amounts added in a 20 mL dispersion of MC1220 loaded liposomes
(with 40 mg/mL lipid concentration) for rheological property adjustment.
Type of agent Amount (g) added in 20 ml liposome dispersion
Natrosol 250 HX 0.30
Carbopol 974 P NF 0.08
Glycerol 0.2
230 M. Caron et al. / Virology 405 (2010) 225–233multiple targets could help combat HIV-1 sequence diversity and
minimize transmission of variants resistant to any single inhibitor
(Veazey et al., 2005). If a topical RT inhibitor like MC1220 results in
virus replication, additional inhibition could be provided by other
inhibitors, targeting viral entry or enhancing defence. Some such
drugs have been developed, such as PRO-2000®, which interferes
with the binding of HIV-1 to the CD4 receptor, and PSC-RANTES,
which targets speciﬁc host cell co-receptors, such as CCR5 (Lederman
et al., 2004); however, hepatotoxicity has been seen with some CCR5
antagonists. Furthermore, MC1220 is a NNRTI that shows a ‘memory
effect’, i.e. the ability to knock out HIV replication in heavily infected
cells and in dendritic cells and PBMCs ex vivo infected with HIV-1
clinical isolates, MC1220 inhibits the different HIV-1 clades with
potencies comparable (A, B, C, D, F1, CRF02, NNRTI resistant C) or
superior (G, CRF01) to those of UC-781 and TMC-120 (Pani et al.,
2001).
As the bioavailability of topical drugs is very low, various approaches
have been taken to increase it (Loftsson and Masson, 2001). Use of an
innocuous chemical (fatty acids, alcohols, amines) or physical (ultra-
sound, iontophoresis…)means could enhance and facilitate diffusion of
the drug through the barrier or affect its permeability. In our study, the
microbicide MC1220 was incorporated into a complex liposomal gel
which allows high amount of drug loading in a small volume of
formulation.
Unexpectedly, the highest dose used provided only partial
protection in Protocol 1. A possible reason for this incomplete dose–
response effect could be the low aqueous solubility of MC1220 (1–
3.5 ppm, depending on the pH of the solution, with 2–2.5 ppm at pH
5.0). Consequently, the amount of bioavailable drug on the vaginal
mucosa did not increase proportionally to the increase in the drug
concentration in the formulation, as demonstrated by the similar
release rates of MC1220 from the 0.5% and 1.5% liposomal formula-
tions. A strategy to tackle this problem has been identiﬁed, and it is
hoped that it will improve the formulation and, subsequently, the
performance of MC1220. A new approach, therefore, by identifying
alternative solutes for MC1220, would increase its solubility in
aqueous media; without causing vaginal irritation, and acting as a
carrier that would improve the release of the drug from the
formulation following its vaginal application. A second approach to
increase the protection provided byMC1220would be to use the active
enantiomer of the drug instead of its racemic mixture that is used
herein. Theoretically this later approach should result in 2 times
whether increase of efﬁcacy.
Münch et al. recently identiﬁed a 20-amino acid virus-inhibitory
peptide that efﬁciently blocks HIV-1 entry by interacting with the
gp41 fusion peptide (Munch et al., 2007). This peptide might also be
included in combination with MC1220 to prevent vaginal transmis-
sion of HIV-1.
In conclusion, we have shown that the microbicide MC1220 can
induce partial protection after intravaginal challenge of rhesus
macaques. We suggest approaches to improving the efﬁcacy of the
product, by using different formulation strategies and/or by using
several microbicides targeting different sites of virus propagation, like
entry inhibitors, adhesion inhibitors and other replication inhibitors.
The challenge is to ﬁnd sufﬁcient ﬁnancial resources for accelerating
microbicide development. First-generation products have shown their
limits; effectiveness trials could now improve protection against the
main types of HIV, especially with synergetic microbicides like
MC1220.
Material and methods
MC1220 formulations in liposomal gel
MC1220 liposomes were prepared using Hydrogenated Egg
PhosphatidylCholine (H-PC) purchased by Lipoid (Germany) andCholesterol (Sigma-Aldrich, France) at 2/1 (mol/mol). The liposomes
were prepared in citrate buffer pH 5.0 which contained 0.2% (w/v)
sodium benzoate as preservative.
After evaluating different techniques of liposome preparation in
terms of encapsulation efﬁciency, a modiﬁed dried-rehydrated vesicle
technique with high liposome loading capacity of MC1220, was
developed (Antimisiaris S.G. et al., unpublished results). Non-
entrapped solid drug was separated of liposomes by sucrose gradient
centrifugation in swing-out bucket tubes, at 15.000 rpm for 30 min.
Then, the liposomal dispersions stay at a temperature above the lipid
transition temperature during 1–2 h for annealing structural defects
of the lipid membrane.
Gel preparation and rheological property adjustment
For the rheological property adjustment of the liposomal formula-
tions, we considered a mixture of Carpobol and Hydroxypropylcellu-
lose polymers which has been previously demonstrated to form gels
with good characteristics for vaginal delivery (Mourtas et al., 2007).
The ideal system would be easy to apply and well distributed to coat
(and thus, protect) the whole surface of the vaginal epithelium. After
application however, the gel has to stay in place under the low stress
conditions applying due to physiological movements of the vaginal
area, and this translates to higher viscosity under low stress
conditions. Consequently, two polymers (Natrosol® and Carbopol
(Stolte-Leeb et al., 2008)) were used for adjustment of the viscosity
and the rheological properties of the gels. Then, Glycerol was added in
all gels in order to prevent dehydration. The ﬁnal composition of the
liposomal gel used in the in vivo experiments is presented in Table 3.
After preparation, gel formulations could be safely stored at 4 °C
until used. Lipid concentration of liposomal dispersions wasmeasured
by the Stewart colorimetric assay (Stewart, 1980), and ﬁnal drug
concentration in the gels was measured by a validated HPLC
technique. Exact lipid and drug concentrations of the various gels
utilized are presented in Table 4.
Animals
Twenty-four healthy, cycling adult female rhesus macaques
(Macaca mulatta) aged 3.7–5.3 years were housed individually in
cages at the primate center of the CIRMF, according to the European
and the United States National Institutes of Health guidelines for
animal care. All the protocols and procedures were approved by the
Ethical Committee of Ile-de-France for animal experimentation and by
the Gabonese ethics committee for animal experimentation and
registered under No. 06-005. The primate center has three veterinar-
ians specialized in primates, comprising an ethologist, a primatologist
and an ecologist. All experiments were conducted under their
supervision.
The macaques were virologically and serologically negative for
Ebola, αHSV, SRV, SIV and STLV. One month prior to virus inoculation,
the animals were treated by a single 30-mg intramuscular injection of
depo-medroxyprogesterone acetate (Depo-Provera, Pﬁzer, France) to
synchronize their menstrual cycles and to thin the vaginal mucosa,
thus increasing their susceptibility to vaginal transmission of virus
(Marx et al., 1996). Before inoculation, each macaque was sedated
Table 4
The gel analysis by Stewrt assay (for lipid measurement) and by HPLC (for MC1220
measurement). The exact amount of MC-1220 incorporated in the different gel types.
Formulation and batch
number
Lipid [in liposomal form]
(mg/ml) H-PC/Chol
(lipoid E PC 3)
MC-1220 concentration
(ppm)
Liposome blank 42.60 –
MC-1220 0.5% liposomal 42.57 5419±239
MC-1220 1.5% liposomal 42.62 16559±465
231M. Caron et al. / Virology 405 (2010) 225–233with ketamine (10 mg/kg intramuscularly; Imalgene 1000, Merial,
France).
Evaluation of the irritation effect after microbicide treatment
Before the initiation of microbicide treatment, vaginal irritation
was evaluated in 15 female macaques in several subgroups receiving
2 ml of various formulations via a urethral catheter to ensure that the
total amount of microbicide was introduced to the vagina. The
method used for the evaluation of the vaginal irritation effect was
previously described by D'Cruz et al. (D'Cruz et al., 2003). Animals
were maintained with the pelvis in a high position for 30 min to
ensure complete gel penetration. Groups of three macaques received
0.5% MC1220 in liposomal gel, 0.1% MC1220 in liposomal gel, or 0.1%
MC1220 without liposomal gel for 4 consecutive days. Two subgroups
of three animals were given liposome alone or gel alone. Bodyweights
and temperature were obtained before each vaginal application.
The individual irritation score was assigned on the basis of a semi-
quantitative scoring system for inﬂammation: 0=none, 1=minimal,
2=mild, 3=moderate, 4=intense. The cumulative scores for ery-
thema and edema formation were: b 4=acceptable, 5–6=marginal
andN6=unacceptable (D'Cruz et al., 2003).
Microbicide treatment and virus challenge
The two protocols used are illustrated in Fig. 1. In Protocol 1 (single
application), ﬁve animals received liposomal gel alone (controls), four
received 0.5% MC1220 in liposomal gel, and ﬁve received 1.5%
MC1220 in liposomal gel. In Protocol 2 (repeated applications), ﬁve
animals were treated by liposomal gel containing 0.5% MC1220 on
days −3, −2, −1 and 0 before RT-SHIV challenge, and ﬁve control
animals received the liposomal gel alone at the same times. In both
protocols, 30 min after the last application of the microbicide, the
animals were infected intravaginally with 4×105 TCID50 of RT-SHIV
(an SIV/HIV hybrid virus in which only the reverse transcriptase of
SIVmac239 was replaced by that of HIV-189.6P) in seminal human
ﬂuid (Uberla et al., 1995) and were followed-up for 10 weeks.
Blood samples were taken every 2 weeks, and PBMCs were
separated by centrifugation in lymphocyte separation media. The
animals were sacriﬁced 14 weeks after infection, and tissue samples
were collected from the spleen and the mesenteric, axillary, inguinal
and iliac lymph nodes.
Determination of plasma RT-SHIV load
After challenge, the presence of RT-SHIV in the plasma was
evaluated by RT-PCR. RNA was extracted from 200 μl of plasma with
the QIAamp® Viral RNAmini kit (Qiagen, France) and eluted in 60 μl of
elution buffer according to the manufacturer's instructions. The viral
load was detected by real-time RT-PCR as previously described
(Hofmann-Lehmann et al., 2002) with the Quantitect RT-PCR Probe
PCR one-step kit (Qiagen, France) on an iCycler iQ5, with primers at a
ﬁnal concentration of 450 nmol/l and with probes at a concentration
of 500 nmol/l. Viral RNA was quantiﬁed by comparison with a
standard curve of log dilutions of cDNA standards (from RT-SHIV)ranging 102 to 108 copies. Samples (10 μl of RNA per reaction) were
run in duplicate. Primers and TaqMan probes were previously
described (Hofmann-Lehmann et al., 2002).
Detection of RT-SHIV proviral load
Genomic DNA was isolated from 140 μl of PBMCs with the
QIAamp® DNA mini kit (Qiagen, France) and eluted in 200 μl of
elution buffer according to the manufacturer's instructions. Proviral
DNA was detected by real-time PCR in the same material (except for
the PCR reagent, which was Quantitect PCR Probe from Qiagen) with
the primers and probe described above. The cycling conditions were
as follows: 95 °C for 10 min, followed by 50 cycles at 95 °C for 10 s and
60 °C for 60 s. Viral DNA was quantiﬁed by comparison with a
standard curve of log dilutions of DNA standards, ranging from 4 to
4×106 copies. Samples (5 μl per reaction) were run in duplicate. To
determine the mean number of cells that contained proviral DNA, we
used parallel ampliﬁcation of albumin. The cycling conditions were
identical to those detailed above. We used the primers AlbF 5'-GCT
GTC ATC TCT TGT GGG CTG T-3' and AlbR 5'-ACT CAT GGG AGC TGC
TGG TTC-3' (ﬁnal concentration, 500 nmol/l each) and the probe AlbT
5'-6FAM-CCT GTC ATG CCC ACA CAA ATC TCT CC-TAMRA-3' (ﬁnal
concentration, 300 nmol/l).
Cell-associated virus load
The cell-associated virus load was determined in a limiting
dilution co-culture assay with C8166 cells and mononuclear cells
from blood and lymphoid organs (spleen and mesenteric, axillary,
inguinal and iliac lymph nodes) as described previously (Stahl-Hennig
et al., 1996). The cell-associated virus load was expressed as the
number of infectious units per 106 PBMCs after 2 weeks of co-culture
in the weeks 2, 3, 4, 6 and 8 after challenge and the week of necropsy.
Plasma and PBMCs were separated by centrifugation on Ficoll density
gradients at 1000g for 15 min in Leucosep separation tubes (Greiner
Bio-One, Germany). Mononuclear cells were obtained from lymphoid
organs by passing the crushed organs through a 40 μm nylon BD
Falcon Cell Strainer (BD Biosciences, Belgium). The PBMCs were also
subjected to ﬂow cytometry and quantitative real-time PCR analysis.
Virus-speciﬁc antibody responses
Antibodies to RT-SHIVSIVmac239 were assessed with Genscreen®
HIV-1/2 version 2 (Biorad, France) according to the manufacturer's
instructions. The plasma samples, diluted 3:4, were tested at the
weeks 1, 2, 4, 6, 8, 10 after challenge and the week of necropsy. The
antibody responses were determined at optical densities of 450 and
620 nm. The serological data were expressed as optical density/cut-
off value, and samples were considered positive atN1.
Lymphocyte phenotype analysis
To identify virus-speciﬁc responses, 30 μl of whole blood were
incubated with 6–12 μl of different combinations of monoclonal
antibodies mixed at room temperature for 15 min in the dark: for CD4
cells, CD45RA FITC(5H9), CD29 PE(MAR4), CD4 PerCP(L200) and CD3
APC(SP34-2); for CD8 cells, CD45RA FITC(5H9), CD29 PE(MAR4), CD8
PerCP(SK1) and CD3 APC(SP34-2); for effector and central memory CD4
cells, CD95FITC(DX2), CD28PE(L293), CD4PerCP(L200) andCD3APC(SP34-2);
and for effector and central memory CD8 cells, CD95 FITC(DX2),
CD28 PE(L293), CD8 PerCP(SK1) and CD3 APC(SP34-2). After addition of
750 μl of lysing solution (Becton Dickinson, Lincoln Park, New York,
USA), incubation proceeded for 5 min at room temperature in the
dark. After centrifugation at 1800 rpm and elimination of the
supernatant, cell ﬁx was added and ﬂow cytometry was performed
232 M. Caron et al. / Virology 405 (2010) 225–233on a FACsort with Flowjo software, 10,000 events being analysed
per sample.
Statistical analysis
For comparison between groups, Mann–Whitney U tests were
performed. Correlations between different sets of data for the same
group were analyzed with either the standard Pearson correlation
coefﬁcient or the Spearman's rank correlation test. Signiﬁcance was
assessed at pb0.05. All analyses were performed with Statistica
software v7.1 (StatSoft France, www.statsoft.fr).
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